Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Shares Outstanding (Weighted Average) (2016)

Lixte Biotechnology Holdings' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $47.9 million for Q3 2016.

  • For Q3 2016, Shares Outstanding (Weighted Average) rose 3.12% year-over-year to $47.9 million; the TTM value through Sep 2016 reached $47.9 million, up 3.12%, while the annual FY2015 figure was $46.8 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $47.9 million in Q3 2016 per LIXT's latest filing, roughly flat from $47.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $47.9 million in Q1 2016 to a low of $2.9 million in Q2 2014.
  • Average Shares Outstanding (Weighted Average) over 5 years is $41.0 million, with a median of $41.6 million recorded in 2013.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 92.96% in 2014, then soared 1494.85% in 2015.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $39.0 million in 2012, then rose by 6.66% to $41.6 million in 2013, then grew by 9.38% to $45.5 million in 2014, then rose by 2.88% to $46.8 million in 2015, then increased by 2.31% to $47.9 million in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Shares Outstanding (Weighted Average) are $47.9 million (Q3 2016), $47.9 million (Q2 2016), and $47.9 million (Q1 2016).